Mental illness related disparities in diabetes prevalence, quality of care and outcomes: a population-based longitudinal study

Qun Mai1*, C D’Arcy J Holman1, Frank M Sanfilippo1, Jonathan D Emery2 and David B Preen1

Abstract

Background: Health care disparity is a public health challenge. We compared the prevalence of diabetes, quality of care and outcomes between mental health clients (MHCs) and non-MHCs.

Methods: This was a population-based longitudinal study of 139,208 MHCs and 294,180 matched non-MHCs in Western Australia (WA) from 1990 to 2006, using linked data of mental health registry, electoral roll registrations, hospital admissions, emergency department attendances, deaths, and Medicare and pharmaceutical benefits claims. Diabetes was identified from hospital diagnoses, prescriptions and diabetes-specific primary care claims (17,045 MHCs, 26,626 non-MHCs). Both univariate and multivariate analyses adjusted for socio-demographic factors and case mix were performed to compare the outcome measures among MHCs, category of mental disorders and non-MHCs.

Results: The prevalence of diabetes was significantly higher in MHCs than in non-MHCs (crude age-sex-standardised point-prevalence of diabetes on 30 June 2006 in those aged ≥20 years, 9.3% vs 6.1%, respectively, \( P < 0.001 \); adjusted odds ratio (OR) 1.40, 95% CI 1.36 to 1.43). Receipt of recommended pathology tests (HbA1c, microalbuminuria, blood lipids) was suboptimal in both groups, but was lower in MHCs (for all tests combined; adjusted OR 0.81, 95% CI 0.78 to 0.85, at one year; and adjusted rate ratio (RR) 0.86, 95% CI 0.84 to 0.88, during the study period). MHCs also had increased risks of hospitalisation for diabetes complications (adjusted RR 1.20, 95% CI 1.17 to 1.24), diabetes-related mortality (1.43, 1.35 to 1.52) and all-cause mortality (1.47, 1.42 to 1.53). The disparities were most marked for alcohol/drug disorders, schizophrenia, affective disorders, other psychoses and personality disorders.

Conclusions: MHCs warrant special attention for primary and secondary prevention of diabetes, especially at the primary care level.

Background

Mental illness carries high risks of morbidity and mortality from physical illness [1-3]. Disparities in access to and the quality of physical health care may contribute to poor physical health outcomes in people with mental illness [4]. Access to care is a prerequisite for quality of care, whilst primary care is a foundation for population health, especially for vulnerable groups, including people with mental illness [5]. Our previous study found that Western Australian mental health clients (MHCs), except homeless MHCs (4%), had substantially more visits to general practitioners (GPs) than non-MHCs [6]. This suggests that, in Australia, with its universal health insurance coverage provided by Medicare [7], it appears unlikely that limited access to primary care explains poor physical health outcomes in MHCs. We, therefore, turned our focus to potential disparities in the quality of primary care using diabetes care as an indicator [8], because: (i) diabetes is a major medical condition and a growing epidemic in the general population [9], (ii) the evidence base for diabetes care is strong, and (iii) primary care is the ideal setting for diabetes care.

Previous research has been limited by cross-sectional study design, focus only on one single mental disorder, or an inability to capture care received outside a particular payment system. Few studies have applied rigorous methods to define the non-diabetic population, or are
population-based, using linked data, or have examined the association with long-term outcomes.

To address these gaps, we used population-based linked data to answer four specific questions: (i) is diabetes prevalence greater in MHCs; (ii) are diabetes quality of care measures worse in MHCs; (iii) are risks of hospitalisation for diabetes complications, diabetes-related mortality and all-cause mortality higher in MHCs; and (iv) do these associations vary by type of mental disorder?

Methods
We conducted a population-based longitudinal study for the period 1 January 1990 to 30 June 2006, using the cross-jurisdictional data linkage facility of the Western Australian Data Linkage System (WADLS) [10].

Data sources
We linked patient-level data from seven datasets in the WADLS, including WA state mental health registry (MHR, 8% of the general population, generally with moderate to severe mental illness), electoral roll registrations (86% of the general population aged ≥18 years), hospital inpatient discharges, emergency department attendances, and death registrations; and Commonwealth Medicare Benefits Scheme claims (MBS, covering GP and pathology services) and Pharmaceutical Benefits Scheme claims (PBS, prescriptions dispensed) (Table 1).

The MHR contained mental health inpatient data from all psychiatric institutions, public and private general hospitals, outpatient data from public mental health clinics, community mental health services and psychiatric residential units. Mental health patients treated only by private psychiatrists or GPs were not included in the MHR.

Study cohorts
To enhance internal validity of the study, we used the electoral roll as the sampling frame for both MHCs and non-MHCs so that both groups were obtained from the same source population (see Figure 1). MHCs were defined as people on the electoral roll who were also in the MHR (about 80% of MHCs) and still alive from 1 January 1990 onwards. Non-MHCs were a random sample of people who were on the electoral roll, but never recorded in the MHR. They were matched 2:1 with MHCs by five-year age group, sex and current electoral roll registration at study entry. For MHCs, the study entry date was 1 January 1990 for patients first recorded in the MHR before 1 January 1990, or the first date of registration on the MHR for those recorded later. The entry date for non-MHCs was the same as that of their matched MHCs.

Diabetes was identified from hospital discharge diagnoses, prescriptions for glucose lowering medications from the PBS, or diabetes-specific GP services or pathology tests for routine glucose monitoring (HbA1c, or fructosamine) from the MBS (Table 1). Three exclusions applied: (i) for people identified only by HbA1c or fructosamine tests, we included only those with at least three tests in any one year, or at least one test in at least three consecutive years; (ii) people prescribed metformin and concurrently diagnosed with polycystic ovary syndrome; and (iii) people with dementia (due to their high use of residential care). This method of identifying diabetic patients using linked data involved extensive consultation with a clinical advisory group to ensure it accurately reflected clinical management of diabetic patients within WA. For the quality and outcome components of the study, the start of follow-up (T0) was the entry date if diabetes was first indicated before then, otherwise it was the date when diabetes was first indicated.

Variables and measurements

Exposure variables
We ascertained the principal mental health diagnosis for each MHC using a previously published method [3], which assigned patients to their most significant mental health diagnosis on an hierarchy of severity (Table 1). People with dementia were excluded after the ascertainment of the principal mental illness. The remaining records were then grouped into one of ten mutually exclusive categories of mental disorders [11].

Outcome measures

Diabetes prevalence. We calculated the age-sex-standardised point prevalence of diabetes on 30 June 2006 in those aged ≥20 years. The denominators were MHCs and non-MHCs who were still alive on 30 June 2006. The numerators were those in the denominators whose diabetes was recorded on or before 30 June 2006. The 2006 estimated residential population of WA was used as the standard population.

Recommended pathology tests were identified from MBS data indicating a test for HbA1c, microalbuminuria or blood lipids (Table 1). Two types of measures were created: (i) cumulative incidence of tests at one year, conditional on at least 365 days of follow-up; and (ii) incidence rate of tests during the entire follow-up period (up to 16.5 years). Two summary measures were also calculated: (i) any test at one year, and (ii) all tests during the entire follow-up period.

Other outcome measures
First hospital admissions for a diabetic complication and diabetes-related deaths were identified using Davis’ criteria (Table 1) [12]. Diabetes-related deaths included those where diabetes was either the underlying or a contributory cause of death. Follow-up time ended at 30 June 2006 or an earlier date of death or, in the case of first admission for a diabetes complication, on the admission date.
Table 1 Summary of study methods

A. Data sources for the study

| Data sources                        | Period    | Records    | Persons   | Key variables                          |
|-------------------------------------|-----------|------------|-----------|----------------------------------------|
| 1. Medicare benefits (MBS)          | 1984 to 2006 | 143,416,764 | 554,541   | GP and pathology services              |
| 2. Pharmaceutical benefits (PBS)    | 1990 to 2006 | 78,467,656  | 475,826   | Prescriptions                          |
| 3. Hospital inpatients*             | 1980 to 2006 | 4,844,745   | 520,236   | Dates, diagnoses and procedures        |
| 4. Mental health registry (MHR)     | 1966 to 2006 | 529,935     | 150,401   | Dates and diagnoses                    |
| - Mental health inpatients*         | 1971 to 2006 | 9,981,236   | 190,440   |                                        |
| 5. Hospital inpatients*             | 1988 to 2006 | 782,161     | 483,524   | Date of registration and updates       |
| 6. Death*                           | 1990 to 2006 | 80,546      | 80,546    | Date of death and cause of death       |
| 7. Emergency department*            | 2001 to 2006 | 990,506     | 248,457   | Date of attendance and diagnosis       |

B. Data sources and codes for identifying diabetes

| Hospital inpatient and ED          | ICD-9 code in any diagnosis field |
|------------------------------------|-----------------------------------|
| - Diabetes                         | 250                               |
| - Polycystic ovary syndrome         | 256.4                             |

| PBS                                | Item                              |
|------------------------------------|-----------------------------------|
| - Oral hypoglycaemic agents        | 1202, 1801, 2178, 2430, 2440, 2449, 2607, 2720, 2939, 2940, 8188, 8189, 8391, 8392, 8450, 8451, 8452, 8533, 8535, 8607, 8687, 8688, 8689, 8690, 8691, 8692, 8693, 8694, 8695, 8696, 8810, 8811, 8838, 8884 |
| - Insulin                          | 1425, 1426, 1429, 1430, 1431, 1461, 1462, 1531, 1532, 1533, 1534, 1535, 1537, 1591, 1592, 1710, 1711, 1713, 1715, 1716, 1717, 1721, 1722, 1761, 1762, 1763, 2061, 2062, 8006, 8084, 8085, 8212, 8390, 8435, 8571, 8609, 8674, 9039, 9094 |

| MBS                                | Item                              |
|------------------------------------|-----------------------------------|
| - GP diabetes annual cycle of care | 2517, 2518, 2521, 2522, 2525, 2526, 2620, 2622, 2624, 2631, 2633, 2635 |
| - HbA1c or fructosamine            | 66551, 66554, 66557, 66319, 66322, 73815, 73840 |

C. Category of mental disorders

| Category                          | ICD-9 principal code |
|-----------------------------------|----------------------|
| - Alcohol/drug disorders          | 291, 292, 303 to 305 |
| - Schizophrenia                   | 295                  |
| - Affective psychoses             | 296                  |
| - Other psychoses                 | 293, 294, 297 to 299 |
| - Neurotic disorders              | 300                  |
| - Personality disorders           | 301                  |
| - Adjustment reaction             | 309                  |
| - Depressive disorder             | 311                  |
| - Other mental disorders          | 302, 306 to 308, 310, 312 to 319 |
| - Other than mental or behavioural disorders | not in 290 to 319 |

D. MBS items for identifying pathology tests for routine diabetes monitoring

| Test                               | Item                              |
|------------------------------------|-----------------------------------|
| Glycated haemoglobin (HbA1c)       | 66551, 66319                       |
| Microalbuminuria                   | 66361, 66560                       |
| Lipids                             | 66317, 66334, 66335, 66337, 66341, 66521, 66524, 66527, 66530, 66533, 66536 |

E. ICD-9 codes for identifying diabetes complications and diabetes-related deaths

| ICD-9 principal diagnosis or procedure codes |
|----------------------------------------------|
| Diabetes/diabetes complications             | 250                                  |
| Circulatory disorders                       |                                      |
| - Hypertension                              | 401 to 405                           |
| - Ischemic heart disease                    | 410 to 414                           |
| - Cerebrovascular disease                   | 430 to 438, 362.34, 784.3            |
| - Heart failure                             | 428, 429.2 to 4293, 4299             |
| - Atherosclerosis                           | 440                                  |
| - Peripheral vascular disease               | 443, 459.8 to 459.9, 444, 447.1      |
Potential confounders

Scores for social disadvantage and residential remoteness were derived from the Index of Relative Socio-Economic Disadvantage (IRSD) [13] and the Accessibility/Remoteness Index of Australia (ARIA) [14] of the Australian Census based on place of residence (address). Social disadvantage scores were grouped into five levels (the lowest 10% of IRSD scores of the WA general population, 10% to < 25%, 25% to < 50%, 50% to < 75% and ≥75%) and remoteness scores were grouped into...
metropolitan, rural and remote. Diabetic treatment was categorised into: no glucose lowering medications, oral hypoglycaemic agents (OHA) only, and insulin with or without OHA. Age, social disadvantage, residential remoteness and calendar year were measured at T₀ (or 30 June 2006 for the prevalence study). Physical comorbidities were measured by the Charlson Index [15] based on inpatient data with a five-year look-back period from T₀ (or 30 June 2006 for the prevalence study). Missing values for each variable were treated as a separate exposure category so that all subjects were included in the multivariate analyses.

Statistical analyses
Patient characteristics and crude outcomes were compared using bivariate analyses (chi-squared or unpaired tests for categorical variables, two-tailed t- or Mann-Whitney tests for continuous variables). We compared MHCs and non-MHCs using univariate and multivariate models for: (i) diabetes prevalence using logistic regression; (ii) receipt of recommended pathology tests using logistic regression (for cumulative incidence) and negative binomial regression (for incidence rates); and (iii) risks of hospitalisation for diabetes complications, diabetes-related mortality and all-cause mortality using Cox regression. Variables adjusted in the multivariate analyses included the five-year age group, sex, Indigenous status, level of social disadvantage, level of residential remoteness, physical comorbidities, calendar year at T₀ and type of diabetic treatment (the latter two were not included in models for diabetes prevalence). We repeated the above analyses comparing non-MHCs with people in each of the 10 categories of mental disorders. Stata version 10.0 for Windows (StataCorp, College Station, TX, USA) was used for all analyses.

Ethics approval
The study was approved by the Human Research Ethics Committees of The University of Western Australia, and health departments of the Australian and WA governments.

Results
Patient characteristics
The study cohorts comprised 139,208 MHCs and 294,180 non-MHCs. Of these, 17,045 MHCs and 26,626 non-MHCs had diabetes. Characteristics of diabetic patients in MHCs and non-MHCs at T₀ are shown in Table 2. Relative to diabetic non-MHCs, diabetic MHCs were more likely to be younger, female, Indigenous, socially disadvantaged, living in rural or remote areas, having worse physical health status and being treated with insulin (all P-values < 0.001). The distribution of mental disorders among diabetic MHCs is also shown in Table 2.

Diabetes prevalence
MHCs with any mental disorders had a higher prevalence of diabetes than non-MHCs (Figures 2 and 3). The overall age-/sex-standardised prevalence at 30 June 2006 for those aged ≥20 was 9.3% vs 6.1%, respectively (P < 0.001; Table 3). After adjustment for socio-demographics and case mix, the overall odds ratio (95% CI) was 1.40 (1.36 to 1.43). The prevalence was highest in patients with schizophrenia, affective psychoses and alcohol/drug disorders (Figure 3).

Receipt of recommended pathology tests
Table 3 shows disparities between diabetic MHCs and non-MHCs in their likelihood of receiving recommended pathology tests for diabetes monitoring at one year and during the entire follow-up period. Unadjusted and adjusted results showed that diabetic MHCs were significantly less likely to receive the pathology tests at one year and during the entire follow-up period. The pattern of results was similar across individual tests (Table 3 and Figure 3). The likelihood of receiving recommended pathology tests were lowest in those with alcohol/drug disorders, other psychoses, depressive disorders and schizophrenia (Figure 3).

Risks of first hospitalisation for complications of diabetes, diabetes-related mortality and all-cause mortality
Diabetic MHCs were at increased risk of hospitalisation for a diabetic complication, or of diabetes-related mortality and all-cause mortality than diabetic non-MHCs in both unadjusted and adjusted analyses (Table 3). Alcohol/drug disorders and personality disorders had the highest risk of hospitalisation for diabetes complications; other psychoses, schizophrenia, alcohol/drug disorders and personality disorders for diabetes-related mortality; and alcohol/drug disorders, other psychoses and schizophrenia for all-cause mortality (Figure 4).

Discussion
We adopted a population-based approach to examine mental illness-related disparities in disease prevalence, quality of care and outcomes for a major medical condition - diabetes. The results showed that MHCs had higher diabetes prevalence, fewer recommended pathology tests for ongoing diabetes monitoring, and higher risks of hospitalisation for diabetes complications, diabetes-related mortality and all-cause mortality, compared with non-MHCs. Disparities were most marked in MHCs with alcohol/drug disorders, schizophrenia, affective disorders, other psychoses and personality disorders.

The strengths of our study compared with previous published studies are the: (i) use of population-based linked data with over 400,000 people in the study populations, (ii) inclusion of a wide spectrum of mental disorders in
Table 2 Characteristics of diabetic patients in MHCs and non-MHCs at the start of follow up (T0)

| Patient characteristic* | MHCs (n = 17,045) | Non MHCs (n = 26,626) |
|-------------------------|-------------------|-----------------------|
| Age, years, %           |                   |                       |
| < 45                    | 20.7%             | 11.5%                 |
| 45 to 54                | 19.7%             | 14.3%                 |
| 55 to 64                | 21.6%             | 20.7%                 |
| 65 to 74                | 18.6%             | 23.2%                 |
| ≥75                     | 19.3%             | 30.3%                 |
| Sex, % male             |                   |                       |
| Indigenous              | 11.8%             | 5.6%                  |
| Non-Indigenous          | 88.1%             | 91.1%                 |
| Missing                 | 0.1%              | 3.3%                  |
| Level of social disadvantage |               |                       |
| Most disadvantaged      | 15.1%             | 10.5%                 |
| More disadvantaged      | 22.7%             | 21.1%                 |
| Little disadvantaged    | 24.5%             | 23.8%                 |
| Less disadvantaged      | 17.3%             | 17.8%                 |
| Least disadvantaged     | 19.0%             | 25.8%                 |
| Missing                 | 1.3%              | 1.0%                  |
| Residential remoteness  |                   |                       |
| Metropolitan            | 64.8%             | 70.9%                 |
| Rural                   | 25.0%             | 22.7%                 |
| Remote                  | 9.8%              | 6.3%                  |
| Missing                 | 0.4%              | 0.1%                  |
| Charlson comorbidity score, mean (SD) | 0.83 (1.62) | 0.63 (1.43) |
| Diabetes recorded before T0, % | 34.8% | 31.6% |
| Type of treatment at one year, % |                   |                       |
| No diabetic medications | 53.1%             | 52.5%                 |
| Oral hypoglycemic agents only | 39.0% | 40.9% |
| Insulin                 | 7.9%              | 6.6%                  |
| Type of treatment at up to 16 years, % |                   |                       |
| No diabetic medications | 33.6%             | 32.6%                 |
| Oral hypoglycemic agents only | 47.7% | 51.0% |
| Insulin                 | 18.7%             | 16.4%                 |
| Type of mental disorders |                   |                       |
| Alcohol/drug disorders  | 8.7%              |                       |
| Schizophrenia           | 4.8%              |                       |
| Affective psychoses     | 18.6%             |                       |
| Other psychoses         | 10.7%             |                       |
| Neurotic disorders      | 17.6%             |                       |
| Personality disorders   | 2.2%              |                       |
| Adjustment reaction     | 5.1%              |                       |
| Depressive disorder     | 4.9%              |                       |
| Other mental disorders  | 5.9%              |                       |
| Other than mental or behavioural disorders | 21.6% | |

Abbreviations: MHCs, mental health clients, SD, standard deviation.
*P < 0.001 for all comparisons.

the analysis, (iii) use of a comparison group of people with no mental illness, (iv) rigorous identification of diabetes within the study populations, and (v) long-term follow-up (up to 16.5 years).

The limitations of our study included, first, the lack of data for private psychiatrists and GPs treating mental disorders. This limits the extrapolation of our findings for people with mental illness in Australia. Patients in
the MHR account for about 40% of people with mental illness (8% of the estimated 20% of Australian adults who have clinically diagnosable mental illness), generally with moderate to severe mental illness. Their physical disease burden and physical health care disparities were probably greater than the remainder of people with mental illness. Nevertheless, using the MHR to identify mental health group as did our previous study [6].
Table 3 Disparities in diabetes prevalence, quality of care and outcomes in MHCs and non-MHCs

| Measure                                                                 | MHCs* (%) | Non-MHCs (%) | Unadjusted OR/RR (95% CI) | Adjusted OR/RR (95% CI)† |
|------------------------------------------------------------------------|-----------|--------------|---------------------------|--------------------------|
| Diabetes prevalence‡, %                                                 | 9.3%      | 6.1%         | 1.41 (1.37 to 1.44)       | 1.40 (1.36 to 1.43)      |
| Receipt of recommended test at one year§, %                            |           |              |                           |                          |
| - HbA1c test                                                           | 37.2%     | 42.9%        | 0.79 (0.76 to 0.82)       | 0.84 (0.80 to 0.88)      |
| - Microalbuminuria test                                                | 12.6%     | 15.4%        | 0.79 (0.74 to 0.84)       | 0.76 (0.71 to 0.82)      |
| - Blood lipid test                                                     | 24.3%     | 29.5%        | 0.77 (0.73 to 0.80)       | 0.81 (0.77 to 0.85)      |
| - Any test                                                             | 46.4%     | 53.2%        | 0.76 (0.73 to 0.80)       | 0.81 (0.78 to 0.85)      |
| Receipt of recommended test during the entire follow-up period, rate per person per year |           |              |                           |                          |
| - HbA1c test                                                           | 0.62      | 0.68         | 0.89 (0.86 to 0.91)       | 0.88 (0.86 to 0.90)      |
| - Microalbuminuria test                                                | 0.24      | 0.27         | 0.86 (0.83 to 0.89)       | 0.82 (0.80 to 0.85)      |
| - Blood lipid test                                                     | 0.40      | 0.44         | 0.90 (0.88 to 0.93)       | 0.90 (0.88 to 0.93)      |
| - All tests                                                            | 1.25      | 1.38         | 0.88 (0.86 to 0.90)       | 0.86 (0.84 to 0.88)      |
| First hospitalisation for diabetes complications, %                    | 45.2%     | 45.0%        | 1.08 (1.05 to 1.12)       | 1.20 (1.17 to 1.24)      |
| Diabetes related mortality, %                                          | 11.8%     | 11.1%        | 1.08 (1.02 to 1.15)       | 1.43 (1.35 to 1.52)      |
| All cause mortality, %                                                 | 30.4%     | 27.1%        | 1.14 (1.10 to 1.19)       | 1.47 (1.42 to 1.53)      |
| Entire follow-up time, y, mean (SD)                                    | 10.5 (5.9) | 10.8 (5.6)   |                           |                          |

*P < 0.001 for each unadjusted comparison of diabetes measures in MHCs and non-MHCs, except first hospitalisation for diabetes complications (P = 0.701) and diabetes related mortality (P = 0.020).
† Confounding variables adjusted in the multivariate analyses included the five-year age group, sex, Indigenous status, level of social disadvantage, level of residential remoteness, physical comorbidities, calendar year and whether diabetes was identified before T0 and type of diabetic treatment (the latter two variables were excluded from the multivariate analyses for diabetes prevalence).
‡ Age-sex-standardised point prevalence on 30 June 2006.
§ Analyses restricted to subset of patients with at least one year of follow-up (14,836 MHCs and 23,974 non-MHCs).

Abbreviations: 95% CI, 95% confidence interval; MHC, mental health client; OR, odds ratio; RR, rate ratio; SD, standard deviation.

Mai et al. BMC Medicine 2011, 9:118
http://www.biomedcentral.com/1741-7015/9/118
ensures the continuity and integrity of our investigations and findings.

Second, while the domain restriction to the WA electoral roll enhanced the internal validity, it reduced the external validity. It is likely that MHCs who were not on the electoral roll have different socio-demographic profiles to MHCs who are on the electoral roll. They may represent a group who are younger than 18 years, have severe mental illness, are homeless, Indigenous, overseas visitors or new migrants [6]. The disparities in this group may be greater. Using Indigenous people as an example, they are known to have high rates of both diabetes and mental illness. They are more likely over-represented in MHCs who were not on the electoral roll and may experience greater barriers to receiving good quality of care. Also the MHR captured only about 40% of patients with mental illness, thus our non-MHC group almost certainly included some people with mental illness. This may result in underestimation of the true difference between MHCs and non-MHCs.

Third, MBS and PBS data do not contain diagnostic information and thus diabetes cases identified from these data are implied rather than definite. However, importantly, we used the same definition to identify diabetes in both groups as the focus of the study was on differences rather than absolute measures. Nevertheless, our diabetes prevalence measures for schizophrenia and affective disorders were consistent with other studies (10 to 15%) [16,17]. Also, regular examinations of eyes and feet, and weight and blood pressure monitoring are all part of a comprehensive ongoing monitoring recommended by the Australian clinical practice guidelines for people with diabetes to prevent the development and progression of macrovascular and microvascular complications [18]. However, MBS does not have enough good data to be able to evaluate these. Fourth, we had no information on lifestyle risk factors or detailed clinical information so the effects of these factors could not be adjusted in the analyses. We also had no information on the clinical decision-making processes leading to pathology testing or hospitalisation, so we can only speculate on the relative roles of patient and doctor in driving or inhibiting the recommended tests or hospitalisation. Last, the ascertainment of diabetes-related death from death certificates may have improved over time, but this would apply equally to both MHCs and non-MHCs.
leading to negligible change in the relative differences reported in this study.

Previous research on the association between mental illness and diabetes prevalence has exclusively focused on a single mental illness (schizophrenia or affective disorders) and almost all investigations have used the general population as their comparison group [16,17] rather than a non-mental health comparison group we used. Our study showed that all evaluated mental disorders were associated with a higher prevalence of diabetes not just people with severe mental illness. Diabetic MHCs received fewer recommended pathology tests than non-MHCs, after adjustment for socio-demographics and case mix, which is consistent with other studies [19,20], except that we also assessed the long-term disparities (up to 16.5 years). This indicates that the quality of diabetes care may be poorer in MHCs as the differences in the intensity of testing for diabetes monitoring cannot be explained by the differences in socio-demographics, case mix or access to primary care. Our finding that diabetic MHCs had a higher rate of diabetes-related hospitalisations than diabetic non-MHCs suggests that diabetic MHCs may have more diabetic complications than diabetic non-MHCs, possibly due to their lower use of monitoring tests [20]. Another possible reason may be because diabetic MHCs have a lower threshold for diabetes-related admissions than diabetic non-MHCs. Among MHCs, schizophrenia had the lowest relative risk of hospitalisation for diabetes complications, possibly because of their higher diabetes-related mortality rate. In fact, schizophrenia had the highest rate of fatal first complication (adjusted rate ratio 2.81, 1.84 to 4.29).

Possible reasons for MHC-related disparities include factors related to the: (i) patient’s cognitive impairment or poor communication skills [21], (ii) provider’s bias against ‘difficult’ patients [22,23], (iii) time constraints of competing conditions [24], and (iv) fragmented health system [25]. The interpersonal aspects of the patient-provider relationship may contribute to more pronounced disparities in quality of care in patients with alcohol/drug disorders and personality disorders [19,26], particularly those with alcohol/drug disorders who are unlikely to receive any preventive care [27].

Our study contributes to emerging evidence which shows that mental illness-related disparities in physical disease burden and physical health care are real and substantial, and present fundamental public health and ethical challenges. While access to care is a prerequisite for good quality care, increasing access may not overcome barriers for good quality care in MHCs. While it is important to promote early detection, diagnosis and treatment of mental illness in primary care settings, attention to physical health conditions in people with existing mental illness is also critical. Given the established overall high rate of GP visits in MHCs [6], there is an opportunity for quality improvement and savings in life-years and costs. Potential interventions to improve physical health care should focus on approaches that highlight both mental health issues and physical care requirements in the consultation. Incentives are required that promote preventive care in the routine management of diabetic patients with comorbid mental illness, particularly those with severe mental illness and behavioural disorders and those with multiple risk factors. Mental and physical health care services need to integrate their efforts to provide a holistic, patient-centred approach to improving health outcomes and quality of life in patients with mental illness and comorbid physical diseases.

Conclusions
People with mental illness warrant special attention for primary and secondary prevention of diabetes, especially at the primary care level.

Abbreviations
ARIA: Accessibility/Remoteness Index of Australia; CI: confidence interval; GP: general practitioner; ICD-9-CM: The International Classification of Diseases, 9th revision, Clinical Modification; IRSD: the Index of Relative Socio-Economic Disadvantage; MBS: Medicare Benefits Scheme; MHCs: mental health clients; MHR: mental health registry; OHA: oral hypoglycaemic agents; OR: odds ratio; PBS: Pharmaceutical Benefits Scheme; RR: rate ratio; T0: the start of follow up; WA: Western Australia; WADLS: Western Australian Data Linkage System

Acknowledgements
We thank both the Commonwealth and Western Australian Departments of Health, and Medicare Australia, for providing the linked datasets for analysis. We also thank the Data Linkage Branch at the Western Australian Department of Health for selecting study cohorts and extracting associated linked records. This study was supported by an Australian National Health and Medical Research Council grant on chronic disease management in primary care (support obtained by CDJH).

Author details
1School of Population Health, The University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia. 2School of Primary, Aboriginal and Rural Health Care, The University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia.

Authors’ contributions
QM and CDJH participated in the conception and design of the overall study, and the formulation of the analysis plan. QM researched data and wrote the manuscript. CDJH and FMS reviewed and edited the manuscript and contributed to the discussion. JDE critically revised the manuscript for important intellectual content. DP advised on the method for identifying diabetes using linked data, and reviewed and edited the manuscript. All authors read and approved the final manuscript.

Authors’ information
Qun Mai, MBBS, MPH, Doctoral Scholar, School of Population Health, The University of Western Australia  C D’Arcy J Holman, MPH, PhD, FAFPHM, Chair in Public Health, School of Population Health, The University of Western Australia  Frank M Santilippo, BPharm, PGDipPharm, PhD, Research Assistant Professor, School of Population Health, The University of Western Australia  Jonathan D Emery, MBChB, DPhil, FRACGP, Chair in General Practice, School of Primary, Aboriginal and Rural Health Care, The University of Western Australia
Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1741-7015/9/118/prepub
doi:10.1186/1741-7015-9-118
Cite this article as: Mai et al: Mental illness related disparities in diabetes prevalence, quality of care and outcomes: a population-based longitudinal study. BMC Medicine 2011 9:118.